A Phase 4 interventional study of Dexmedetomidine Hydrochloride and normal saline in Cognitive Impairment, sponsored by Minia University Hospital. Recruiting at 1 site in Egypt. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-15.
Sponsored by Minia University Hospital · Phase 4, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing dexmedetomidine in Cognitive Dysfunction — 3 open to participants now, 5 under way, none of them phase 3. Dexmedetomidine · Cognitive Dysfunction.
Among the 13 studies testing dexmedetomidine in Cognitive Dysfunction, this one is the 6th largest by planned enrollment, is one of 2 that started in 2024, is one of 7 in phase 4, and was the 10th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →3 of the 13 studies testing dexmedetomidine in Cognitive Dysfunction are open now, in 3 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 60+
Peking University First Hospital · Sites in China
Ages 60+
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 4 7
First in 2004; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 94 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 90 across the 13 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
Minia University Hospital is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Minia University Hospital has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
1 of the studies testing dexmedetomidine in Cognitive Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07610343Peking University First HospitalIntranasal Dexmedetomidine-esketamine on Sleep and Cognition in Older Adults With Mild-to-moderate Cognitive Impairment | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing dexmedetomidine in Cognitive Dysfunction, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the effect of Dexmedetomidine on serum Tau-217 protein and its relation to the incidence and severity of postoperative cognitive dysfunction in elderly patients undergoing major surgery under general anesthesia.
to assess the effect of dexmedetomidine on serum Tau-217 protein through measuring serum Tau-217 protein preoperative and postoperative period and comparing the 2 measurements , assessing the cognitive dysfunction in the elderly patients and comparing the correlation between the cognitive dysfunction with serum tau-217 level also assessing the neuroprotective effect of dexmedetomidine on postoperative cognitive dysfunction and its relation with serum Tau-217 level.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Will receive induction of general anesthesia by loading dose of dexmedetomidine (Precedex) 0.6 μg/kg over 10 minutes in a 20 ml micropump, fentanyl in a dose of 1 μg /kg, propofol 1-1.5 mg/kg, and endotracheal intubation will be facilitated by 0.5mg/kg of atracurium and maintenance of anesthesia will be achieved by dexmedetomidine in a dose of 0.3 μg/kg/hr on 50 ml micropump and isoflurane (1-2%) in oxygen-air mixture.
Drug: Dexmedetomidine Hydrochloride
Will receive induction of general anesthesia by infusion of normal saline 20 ml micropump over 10 min, fentanyl in a dose of 1 μg/kg, propofol 1-1.5 mg/kg and endotracheal intubation will be facilitated by 0.5mg/kg of atracurium and maintenance of anesthesia will be achieved by isoflurane (1-2%) in oxygen-air mixture and infusion of 50 ml/hr micropump of normal saline.
Other: normal saline
dexmedetomidine effect in preventing postoperative cognitive dysfunction on elderly patients undergoing major surgery guided with serum Tau-217 protein.
Also known as: precedex
normal saline will be administrated in placebo group
the effect of dexmedetomidine on serum Tau-217 protein value.
estimation of the effect of dexmedetomidine on serum Tau-217 protein in postoperative period.
Time frame: 2 years
to evaluate the postoperative cognitive dysfunction using Mini-Mental State Scale in both the placebo and dexmedetomidine group.
evaluation of the postoperative cognitive dysfunction by Mini Mental State Scale as \>25 is recorded normal while less than \<24 is positive for cognitive dysfunction.
Time frame: 2 years
Heart Rate changes in the intraoperative period after induction of anesthesia and every 10 minutes till the end of surgery and postoperative period after 1 hour and every hour till 6 hours postoperative then every 6 hours
Heart Rate will be measured in beat/min
Time frame: 2 years
Mean Arterial Blood Pressure changes in the intraoperative period after induction of anesthesia and every 10 minutes till the end of surgery and postoperative period after 1 hour and every hour till 6 hours postoperative then every 6 hours
Mean Arterial Blood Pressure will be measured in mmHg/min
Time frame: 2 years
Plan to share: Undecided
Start is estimated for Apr 2024; primary completion for Mar 2025, 11 months later.
Of 43 non-industry phase 4 interventional studies under Cognitive Dysfunction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 69. This study's planned 11 months is below that.
Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 20 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Minia University Hospital